Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on IDEAYA Biosciences (IDYA) today and set a price target of $25.00. The company’s shares closed last Thursday at $13.70.
According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 28.2% and a 55.1% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, Rocket Pharmaceuticals, and Ionis Pharmaceuticals.
IDEAYA Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $24.50, which is a 77.8% upside from current levels. In a report issued on July 9, H.C. Wainwright also maintained a Buy rating on the stock with a $22.00 price target.
See today’s analyst top recommended stocks >>
Based on IDEAYA Biosciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $12.04 million. In comparison, last year the company had a GAAP net loss of $9.57 million.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IDYA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IDEAYA Biosciences, Inc. develops cancer therapeutics. It is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company operates and manages its business as one operating and reportable segment, which is the business of research and development for oncology-focused precision medicine. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.
